Department of Surgery, The Johns Hopkins Hospital, Baltimore, Maryland.
R. Adams Cowley Shock Trauma Center, Baltimore, Maryland.
JAMA Netw Open. 2021 Dec 1;4(12):e2137515. doi: 10.1001/jamanetworkopen.2021.37515.
The frequency of use of endovenous thermal ablation (EVTA) to treat chronic venous insufficiency has increased rapidly in the US. Wide variability in EVTA use among physicians has been documented, and standard EVTA rates were defined in the 2017 Medicare database.
To assess whether providing individualized physician performance reports is associated with reduced variability in EVTA use and cost savings.
DESIGN, SETTING, AND PARTICIPANTS: This prospective quality improvement study used data from all US Medicare patients aged 18 years or older who underwent at least 1 EVTA between January 1, 2017, and December 31, 2017, and between January 1, 2019, and December 31, 2019. All US physicians who performed at least 11 EVTAs yearly for Medicare patients in 2017 and 2019 were included in the assessment.
A performance report comprising individual physician EVTA use per patient with peer-benchmarking data was distributed to all physicians in November 2018.
The mean number of EVTAs performed per patient was calculated for each physician. Physicians who performed 3.4 or more EVTA procedures per patient per year were considered outliers. The change in the number of procedures from 2017 to 2019 was analyzed overall and by inlier and outlier status. An economic analysis was also performed to estimate the cost savings associated with the intervention.
A total of 188 976 patients (102 222 in 2017 and 86 754 in 2019) who had an EVTA performed by 1558 physicians were included in the analysis. The median patient age was 72.2 years (IQR, 67.9-77.8 years); 67.3% of patients were female, and 84.9% were White. Among all physicians, the mean (SD) number of EVTAs per patient decreased from 2017 to 2019 (1.97 [0.85] vs 1.89 [0.77]; P < .001). There was a modest decrease in the mean number of EVTAs per patient among inlier physicians (1.83 [0.57] vs 1.78 [0.55]; P < .001) and a more substantial decrease among outlier physicians (4.40 [1.01] vs 3.67 [1.41] ; P < .001). Outliers in 2017 consisted of 90 physicians, of whom 71 (78.9%) reduced their EVTA use after the intervention. The number of EVTAs per patient decreased by a mean (SD) of 0.09 (0.46) procedures overall (median, 0.10 procedures [IQR, -0.10 to 0.30 procedures]; P < .001). The estimated cost savings associated with the decrease was $6.3 million in 2019.
In this quality improvement study, substantial variability in the number of EVTAs performed per patient was observed across the US. When physicians were provided with a 1-time peer-benchmarked performance report card, the timing of the intervention was associated with a significant decrease in the number of EVTAs performed per patient, particularly among outlier physicians. This quality improvement initiative was associated with reduced variability in EVTA use in the US and a substantial savings for Medicare.
在美国,静脉内热消融 (EVTA) 治疗慢性静脉功能不全的使用频率迅速增加。已经记录了医生之间 EVTA 使用的广泛差异,并且在 2017 年医疗保险数据库中定义了标准的 EVTA 率。
评估提供个性化医生绩效报告是否与降低 EVTA 使用的变异性和节省成本有关。
设计、设置和参与者:这是一项前瞻性质量改进研究,使用了 2017 年 1 月 1 日至 2017 年 12 月 31 日和 2019 年 1 月 1 日至 2019 年 12 月 31 日期间至少接受过 1 次 EVTA 的所有美国 Medicare 患者的数据。所有在 2017 年和 2019 年每年为 Medicare 患者进行至少 11 次 EVTA 的美国医生都被纳入评估。
2018 年 11 月向所有医生分发了一份包含每位患者 EVTA 使用情况和同行基准数据的绩效报告。
为每位医生计算了每位患者进行的 EVTA 平均数量。每年每位患者进行 3.4 次或更多 EVTA 手术的医生被认为是异常值。从 2017 年到 2019 年,对手术数量的变化进行了总体分析,并按异常值和正常值状态进行了分析。还进行了经济分析,以估计与干预相关的成本节约。
共纳入了 188976 名患者(2017 年 102222 名和 2019 年 86754 名),这些患者由 1558 名医生进行了 EVTA。患者的中位年龄为 72.2 岁(IQR,67.9-77.8 岁);67.3%的患者为女性,84.9%为白人。在所有医生中,每位患者的 EVTA 数量从 2017 年到 2019 年有所减少(1.97 [0.85] vs 1.89 [0.77];P<0.001)。在正常值医生中,每位患者的 EVTA 数量适度减少(1.83 [0.57] vs 1.78 [0.55];P<0.001),而在异常值医生中则明显减少(4.40 [1.01] vs 3.67 [1.41];P<0.001)。2017 年的异常值包括 90 名医生,其中 71 名(78.9%)在干预后减少了 EVTA 的使用。每位患者的 EVTA 数量平均减少 0.09(0.46)次(中位数为 0.10 次[IQR,-0.10 至 0.30 次];P<0.001)。与减少相关的估计节省成本为 2019 年 630 万美元。
在这项质量改进研究中,在美国观察到每位患者进行的 EVTA 数量存在很大差异。当医生获得一次性同行基准绩效报告卡时,干预的时间与每位患者进行的 EVTA 数量显著减少有关,尤其是在异常值医生中。这项质量改进计划与美国 EVTA 使用的变异性降低和医疗保险的大量节省有关。